Replies to post #110551 on Biotech Values

[genisi]

I think Teva would only do this [laquinimod] if MNTA was successful in its copaxone program.

I think Teva wanted to have an oral MS candidate knowing these treatments were highly anticipated in the field. Also, collaboration with Active Biotech was announced in mid 2004 after laquinimod phase II data presented at the AAN meeting and a generic threat was not really on the radar screen yet, but other orals were (GSK-683699, FTY-720).